Journal ArticleDOI
PD-1/PD-L1 axis importance and tumor microenvironment immune cells
Parisa Lotfinejad,Tohid Kazemi,Ahad Mokhtarzadeh,Dariush Shanehbandi,Farhad Jadidi Niaragh,Sahar Safaei,Milad Asadi,Behzad Baradaran +7 more
TLDR
A review of clinical trials with the immunotherapy-based treatment of different cancers focuses on the signaling pathway that controls PD-L1 expression and continues with CAR T-cell therapy and siRNA as novel strategies and potential tools in targeted therapy.About:
This article is published in Life Sciences.The article was published on 2020-10-15. It has received 20 citations till now. The article focuses on the topics: Targeted therapy & Breast cancer.read more
Citations
More filters
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams,Robert Gray,Sandra Demaria,Lori J. Goldstein,Edith A. Perez,Lawrence N. Shulman,Silvana Martino,Molin Wang,Vicky Jones,Thomas J. Saphner,Antonio C. Wolff,William C. Wood,Nancy E. Davidson,George W. Sledge,Joseph A. Sparano,Sunil Badve +15 more
TL;DR: In this article, the authors validate the prognostic impact of tumor-infiltrating lymphocytes (TILs) in primary triple-negative breast cancer (TNBC) in two adjuvant phase III trials conducted by the Eastern Cooperative Oncology Group (ECOG).
Journal ArticleDOI
Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status
TL;DR: A review of the clinical applications of photodynamic diagnosis in cancer, including the diagnostic and therapeutic approaches, is provided in this article, where a better understanding of the effectiveness of a combination setting in the clinic as well as the optimization of such complex multimodal treatments may expand the clinical application of PDT.
Journal ArticleDOI
The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer
TL;DR: In this article , the composition and function of immune cells in triple negative breast cancer (TNBC) microenvironment and summarize the major cytokine growth factors and chemokines in the TNBC microenvironment.
Journal ArticleDOI
The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer
Yisheng Fan,Shuai He +1 more
TL;DR: The composition and function of immune cells in the TNBC microenvironment is described and the major cytokine growth factors and chemokines in theTNBC micro environment are summarized.
Journal ArticleDOI
Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges.
TL;DR: In this article, a review of CAR T-cell therapy and its specificity and safety in adoptive cell transfers in breast cancer is presented, highlighting novel discoveries in CAR-T-cell immunotherapy and the formidable barriers including suppression of Tcell function and localization at tumor sites.
References
More filters
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer,Scott S. Tykodi,Scott S. Tykodi,Laura Q.M. Chow,Wen-Jen Hwu,Suzanne L. Topalian,Patrick Hwu,Charles G. Drake,Luis H. Camacho,John S. Kauh,Kunle Odunsi,Henry C. Pitot,Omid Hamid,Shailender Bhatia,Renato G. Martins,Keith D. Eaton,Shuming Chen,Theresa M. Salay,Suresh Alaparthy,Joseph F. Grosso,Alan J. Korman,Susan M. Parker,Shruti Agrawal,Stacie M. Goldberg,Drew M. Pardoll,Ashok Kumar Gupta,Jon M. Wigginton +26 more
TL;DR: Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Journal ArticleDOI
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert,Caroline Robert,Caroline Robert,Jacob Schachter,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Omid Hamid,Christine Mateus,Christine Mateus,Ronnie Shapira-Frommer,Ronnie Shapira-Frommer,Michele Kosh,Honghong Zhou,Nageatte Ibrahim,Scot Ebbinghaus,Antoni Ribas +26 more
TL;DR: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.
Journal ArticleDOI
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
Haidong Dong,Scott E. Strome,Diva R. Salomao,Hideto Tamura,Fumiya Hirano,Dallas B. Flies,Patrick C. Roche,Jun Lu,Gefeng Zhu,Koji Tamada,Vanda A. Lennon,Esteban Celis,Lieping Chen +12 more
TL;DR: It is reported here that, except for cells of the macrophage lineage, normal human tissues do not express B7-H1 and the findings have implications for the design of T cell–based cancer immunotherapy.
Journal ArticleDOI
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann,Joshua A. Bauer,Xi Chen,Melinda E. Sanders,A. Bapsi Chakravarthy,Yu Shyr,Jennifer A. Pietenpol +6 more
TL;DR: Gen expression profiles from 21 breast cancer data sets and identified 587 TNBC cases may be useful in biomarker selection, drug discovery, and clinical trial design that will enable alignment of TNBC patients to appropriate targeted therapies.
Related Papers (5)
Checkpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from here
Maryann J. Kwa,Sylvia Adams +1 more
Triple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm
Mary L. Disis,Sasha E. Stanton +1 more